REGENERON PHARMACEUTICALS/ US75886F1075 /
3/6/2024 6:32:58 PM | Chg. +32.00 | Volume | Bid3:01:04 AM | Ask3:01:04 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
895.00EUR | +3.71% | 4 Turnover: 3,580 |
-Bid Size: - | -Ask Size: - | 100.2 bill.EUR | - | - |
GlobeNewswire
5/20
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire
5/20
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
5/20
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire
5/20
Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encou...
GlobeNewswire
5/17
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International ...
GlobeNewswire
5/14
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Sci...
GlobeNewswire
5/13
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
5/10
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
5/9
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company P...
GlobeNewswire
5/8
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...
GlobeNewswire
5/7
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
GlobeNewswire
4/29
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...
GlobeNewswire
4/25
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...
GlobeNewswire
4/24
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...
GlobeNewswire
4/23
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
GlobeNewswire
4/22
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...
GlobeNewswire
4/18
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals,...
GlobeNewswire
4/18
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Beh...
GlobeNewswire
4/16
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024